Compare CDP & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | ARQT |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | 354 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 1996 | 2020 |
| Metric | CDP | ARQT |
|---|---|---|
| Price | $32.44 | $27.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $38.50 | ★ $40.38 |
| AVG Volume (30 Days) | 720.9K | ★ 2.0M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | 8.94 | ★ 88.79 |
| EPS | ★ 1.15 | 0.09 |
| Revenue | ★ $763,923,000.00 | $376,072,000.00 |
| Revenue This Year | $3.18 | $44.19 |
| Revenue Next Year | $2.94 | $29.31 |
| P/E Ratio | ★ $28.50 | $303.72 |
| Revenue Growth | 1.41 | ★ 91.34 |
| 52 Week Low | $27.06 | $19.30 |
| 52 Week High | $38.90 | $34.80 |
| Indicator | CDP | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 44.63 |
| Support Level | $30.95 | $25.08 |
| Resistance Level | $32.97 | $28.67 |
| Average True Range (ATR) | 0.67 | 1.59 |
| MACD | -0.00 | -0.34 |
| Stochastic Oscillator | 42.67 | 20.32 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. The company has two reportable segments: Defense/IT Portfolio; and Other. Defense/IT Portfolio includes sub-segments such as: Fort George G. Meade and the Baltimore/Washington Corridor (Fort Meade/BW Corridor); Redstone Arsenal in Huntsville, Alabama; Northern Virginia Defense/IT Locations (NoVA Defense/IT); Lackland Air Force Base in San Antonio, Texas; locations serving the U.S. Navy (Navy Support); and data center shells in Northern Virginia.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.